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Centricity are compared with national US data (NHANES,
NHIS, Kaiser Family Foundation and Census) including demo-
graphics and two common diseases, hypertension and diabetes.
Data from 2004 and 2005 are used for all comparisons. EMR
data is included for all patients with activity in 2005. ICD-9
codes were used to identify patients. FBG levels were used in
NHANES patients for diabetes. RESULTS: In total, 3,127,682
EMR patients were available; 2,644,181 of these were 18 and
older. EMR population was older than the general US popula-
tion. A percentage of EMR patients was lower in <18 and 18–44,
and higher in 45–64, 65–74, and 75+. EMR patients had pre-
dominantly commercial insurance (73.0%) and those with Med-
icaid were lower and Medicare higher than the US population.
Racial distribution was similar with EMR having a lower per-
centage of white patients (78.8%, 81.0%) and a higher percent-
age of black patients (13.5%, 12.7%). EMR patients were
overrepresented in the Northeast and Midwest and underrepre-
sented in the West and South and were predominantly female
(59.9%). A total of 683,936 hypertensive EMR patients were
identiﬁed (258.7/1000) as compared with 248.7/1000 (NHIS).
Prevalence of hypertension in EMR patients was higher in
males than females (286.6/1000 vs. 240.0/1000). Adult diabetic
patients were overrepresented in the EMR with 97.8/1000 vs
71.7/1000 (NHIS) and 58.6/1000 (NHANES (FPG > 125 mg/
dl)). CONCLUSION: EMR patients are older than the US popu-
lation and more likely to be female. Prevalence values were
similar for hypertension and higher in EMR patients for diabetes.
This may reﬂect the fact that the EMR is used primarily in
ambulatory primary care practices. EMR data is generally rep-
resentative of the US population but differences may exist
depending on the disease and population of interest.
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OBJECTIVES: The gap between “efﬁcacy” in clinical trials and
“effectiveness” in real practice due to patient selection, non-
compliance and treatment patterns has been broadly recognized
among health-care decision makers. However little attention has
been paid for statistical errors accompanied in clinical trials,
which may cause the gap. The purpose of this study is to develop
a new analytical framework to estimate the degree of the gap
caused by statistical errors. METHODS: The expected cost-
effectiveness ratio (QP) in the real world was formulated in terms
of a vector by using a decision analytic approach assuming an
evidence-based treatment choice from two treatment options: a
new treatment (TA) and a conventional treatment (TB). The
value of QP varies depending on the parameters such as cost-
effectiveness evidence of TA and TB, type  and type  errors,
and a Bayesian prior probability that TA is better than TB. The
prior probability is usually estimated by the following two steps:
1) Bayesian inference based on binomial modeling, and 2)
Normal approximation of the binomial modeling with the log
odds ratio. Then the derived prior probability was applied for
our formula to estimate the gap, called “gap formula”, by using
a hypothetical dataset. In addition, a Monte Carlo simulation
was performed as probabilistic sensitivity analysis. RESULTS:
Adaptive estimations of Bayes provided ﬂexible evaluation for
the gap formula between real world and clinical trials. The result
of the Monte Carlo simulations quantitatively illustrated with
distributions how much the QP could be deviated, mainly
depending on the type  error, from the ideal average cost-
effectiveness ratio. CONCLUSION: The series of methods we
developed can be applied in adaptive design for trial-based cost-
effectiveness analyses such as sample-size calculation considering
the inﬂuence of statistical errors.
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OBJECTIVES: In probabilistic sensitivity analysis of a cost-
effectiveness (CE) study, the unknown parameters, like transition
probabilities, are considered random variables. A crucial ques-
tion is what probabilistic distribution is suitable as synthesizing
the available information (mainly data from clinical trials) about
these parameters. In this context, it has been recognized the
important role of the Bayesian methodology, under which, the
parameters are of random nature.
Despite the great appealing of the Bayesian approach to proba-
bilistic sensitivity analysis, the “lack of objectivity” has been
frequently argued as the main issue precluding the adoption of
Bayesian techniques. This legitime concern has inspired the
development of formal objective priors over the last decades.
These priors are obtained as the result of mathematical formal
rules applied to the models at hand and lead to Bayesian analyses
inﬂuenced only by the data at hand. Formal objective priors have
a number of appealing properties, including excellent frequentist
behaviour.
We explore, in the context of CE analyses, how formal
objective Bayesian methods can be implemented. Speciﬁcally,
we consider two problems that frequently appear in the CE
literature: survival analysis and meta-analysis. We describe in
detail the numerical methods that needs to be used to obtain the
results.
The methodology is fully illustrated using two CE analysis
published in the literature. We compare our results with those
obtained with other approaches to probabilistic sensitivity analy-
sis. We conclude that the differences, when compared with other
approaches, can be quite quite marked, specially when the
number of patients enrolled in the simulated cohort under study
is large.
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OBJECTIVES: Probabilistic sensitivity analysis (PSA) of eco-
nomic evaluations has become more important because decision
makers want to know how uncertain results are. We evaluated
the consistency of PSA methods and how well they adhered
to published recommendations. METHODS: Publications of
methodological guidelines on the conduct of PSA were re-
viewed by three researchers, and a consensus set of criteria
for assessing PSAs were developed. English language health
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economic evaluations based on models, published in 2006 were
obtained from a PubMed search using terms “probabilistic sen-
sitivity” or “probabilistic uncertainty”. Methodological items
were extracted from each article and independently evaluated
against the criteria by each researcher. Disagreements between
evaluations were resolved through voting by the entire research
team. RESULTS: All 43 economic evaluations identiﬁed by the
search criteria were reviewed. 86% varied probability and
utility inputs but only a minority (25%) did so for cost and
resource use inputs. 79% of the studies reported parameter
ranges used in the PSA but only half provided rationale for the
ranges selected. The majority of analyses (65%) used a single
data source to inform distributions, rather than attempt to inte-
grate ﬁndings from multiple studies. Parameter correlation was
only addressed in one instance and only two studies incorpo-
rated structural uncertainty in their analyses. In half of the
studies, PSA was the only type of sensitivity analysis con-
ducted, with no one- or multi-way sensitivity analyses. Cost-
effectiveness acceptability curves derived from the PSAs were
presented in all cases. Less than 10% of studies discussed limi-
tations of their PSA. CONCLUSION: Although PSA has been
pushed as standard practice for economic evaluations, the
quality of these analyses was mixed. Greater consistency in
terms of inclusion of inputs varied and more transparency in
describing development of input probability distributions in the
conduct of PSAs should improve quality and cross-study com-
parability of results.
PMC5
USE OF A DIAGNOSIS-BASED RISK ADJUSTMENT MODELTO
ESTIMATE COSTS OF INDIGENT CARE IN A COMMUNITY AT
MEDICAID REIMBURSEMENT RATES
Leslie RC1, Shepherd MD1, Simmons SC2
1University of Texas at Austin, Austin,TX, USA, 2Indigent Care
Collaboration, Austin,TX, USA
OBJECTIVES: The Indigent Care Collaboration (ICC) gathers
data on hospital and clinic visits for medically indigent patients
in the Austin, Texas, area. However, obtaining cost data is
challenging within, and especially across, partner providers. A
validated cost model would be instrumental in developing pro-
grams and initiatives to improve care. The objectives of this
study were to estimate the annual costs of Austin, Texas, area
medically indigent patients and to describe the prevalence and
costs of chronic diseases and conditions using a diagnosis-based
risk adjustment model. METHODS: This study used the Diag-
nostic Cost Groups (DCG) prospective Medicaid All-
Encounters model, which uses diagnoses, age, and gender to
assign relative risk (RR) scores to patients. The RR scores were
multiplied by the per capita Texas Medicaid expenditure to
obtain estimated annual costs. Chronic diseases were described
in terms of prevalence and total estimated annual cost.
RESULTS: A total of 471,194 encounters were recorded for
163,729 patients meeting the study inclusion criteria between
March 1, 2004, and February 28, 2005. The mean estimated
patient yearly cost was $1,306.81, and the total estimated
yearly population cost was $228,909,529. The most common
chronic diseases and conditions included hypertension, diabe-
tes, depression, substance abuse, pregnancy, asthma, chronic
obstructive pulmonary disease (COPD), and congestive heart
failure (CHF). CONCLUSION: This study demonstrates how
the unknown costs associated with caring for medically indi-
gent patients in a community can be estimated at Medicaid
reimbursement rates using the DCG model on aggregated
patient encounter data.
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OBJECTIVES: The concept of efﬁcient frontier, given a series of
cost-effectiveness estimates for different levels of programs, plays
an important role in the incremental analysis. The purpose of the
study is to exploit a theoretical aspect of the incremental cost-
effectiveness ratios (ICERs) in the context of the efﬁcient frontier
curve, and then to identify the upper and lower limits that bound
the ICER, considering a potential application of the limits for the
pricing rule based on the ICER. METHODS: Let two points be
PA(Ea, Ca) and PB(Eb, Cb) for programs A and B, respectively,
on the E-C plane representing a set of effectiveness and cost.
Theoretical developments were undertaken to ﬁnd a solution for
the question on the boundaries, supposed there exists a concave
graph of the efﬁcient frontier curve, C = f(E), directing upward
from zero on the E-C plane. Model calculation was performed,
for an example, when the curve is a quadratic function estimated
as C = pE2 + qE + r (p, q, and r: constants). RESULTS: The inter-
val with the derivatives:(f ’(Ea), f ’(Eb)) on C = f(E), respectively,
at the points PA and PB was identiﬁed as a solution, called
‘operative interval,’ which describes reasonable lower/upper
boundaries of the ICER, considering the conﬁguration of the
graph. When the efﬁcient frontier curve is quadratic, the width of
the interval was estimated as 2p(DE). Namely, the width is vari-
able, not constant, depending on both p and DE. Furthermore,
the new benchmark identiﬁed four possible scenarios for making
a decision to accept the ICER compared with a threshold of
willingness-to-pay. CONCLUSION: The concept of the opera-
tive interval of an ICER has been introduced, and it suggested
potential usefulness for assessing the acceptability.
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OBJECTIVES: To explore the contribution made by disease
transmission modelling to cost effectiveness analyses.
METHODS: Traditional cost-effectiveness analysis quantiﬁes the
costs and effects accumulated by an average individual exposed
to a particular intervention, relative to one or more suitable
comparators. When reacting to an infectious disease, however,
many interventions alter the natural history of an infection or
individuals’ behaviour in ways that affect the onward transmis-
sion of the pathogen. This, in turn, may inﬂuence the number of
secondary infections generated by each infectious case. For a
cost-effectiveness analysis to account for the averted/additional
cases, a population level perspective including disease transmis-
sion modelling is required, but this comes at a cost. Transmission
models take time to construct and parameterise and are often
data hungry. Do the insights these models provide justify the
investment in time and expertise they require? RESULTS:
This exposition outlines the basic concepts underlying disease
transmission modelling, presents a simple model for a directly
transmitted disease (such as inﬂuenza) and demonstrates the
enormous impact population level effects can have on the
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